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Abstract
Oncolytic herpes simplex virus-1 (oHSV)–based vectors selectively replicate in tumor cells
causing direct killing, ie., oncolysis, while sparing normal cells. oHSV’sare promising anticancer
agents, but their efficacy, when used as single agents, leaves room for improvement. We
hypothesized that combining the direct oncolytic and antiangiogenic activities of the IL-12
secreting NV1042 oHSV with microtubule disrupting agents (MDA’s) would be an effective
means to enhance antitumor efficacy. Vinblastine (VB) was identified among several MDA’s
screened that displayed consistent and potent cytotoxic killing of both prostate cancer and
endothelial cell lines. In matrigel tube forming assays, VB was found to be highly effective at
inhibiting tube formation of HUVEC cells. The combination of VB with NV1023 (the parental
virus lacking IL-12) or NV1042 showed additive or synergistic activity against prostate cancer cell
lines and was not due to increased oHSV replication by VB. In athymic mice bearing CWR22
prostate tumors, VB in combination with NV1042 was superior to the combination of VB plus
NV1023 in reducing tumor burden, appeared to be nontoxic and resulted in a statistically
significant diminution in the number of CD31+ cells as compared to other treatment groups. In
human organotypic cultures using surgical samples from radical prostatectomies, both NV1023
and NV1042 were localized specifically to the epithelial cells of prostatic glands but not to the
surrounding stroma. These data highlight the therapeutic advantage of combining the dual-acting
anti-tumor and anti-angiogenic activities of oHSV’s and MDA’s.
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Introduction
Selectively replication-competent viral vectors, such as oncolytic herpes simplex viruses
type 1 (oHSVs) are genetically engineered from herpes-simplex virus (HSV) type I. These
lytic viruses represent an attractive strategy for tumor-based therapies because they can
specifically replicate and spread in cancer cells in situ, exhibiting oncolytic activity through
direct cytopathic effects while sparing normal cells. Since the first report of a conditionally
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replicating genetically engineered virus1, a number of oHSV vectors have been developed
which are highly effective against a myriad of solid tumors2-5. For example, NV1023 and
the IL-12 expressing NV1042, are derived from an HSV1/2 intertypic mutant, which retains
one copy of gamma34.5 gene6. NV1042 has been shown to inhibit squamous cell carcinoma
growth through both antiangiogenic mechanisms as well as direct cytopathic effects7. We
have shown that NV1042 is superior to the NV1023 parent vector in inhibiting prostate
cancer growth of both primary and metastatic tumors via both immune and antiangiogenic
mechanisms in syngeneic mouse models8-10. The antiangiogenic activity is due, in part, to
the induction of IFNγ pro-inflammatory activities11. IFNγ affects the neovasculature
through induction of the angiostatic chemokines CXCL9 (MIG) and CXCL10 (IP-10), up-
regulation of VCAM-1 and inhibition of MMP9 expression12. Although IL-12 is also known
to enhance antitumor response by inducing a Th1 response, it has also been shown that
blood vessel formation is markedly decreased by IL-12 treatment in severe-combined
immunodeficient (SCID) mice11, suggesting that the antiangiogenic effects of IL-12 is
independent of T and B-cells.
Previously, we reported that the combination of oHSV plus a microtubule disrupting agent
(MDA), ie.,docetaxel or paclitaxel, acts synergistically to promote prostate cancer cell
killing in vitro and in vivo13. Similar synergestic interactions have been reported for another
HSV-1 mutant as well as for vaccinia virus and reovirus in various cancers including
prostate cancer14-16. In addition, studies involving the use of adenovirus mutants in
combination with either paclitaxel or docetaxel have reported synergistic interactions in
prostate cancer cells17,18. MDA’s have been shown to be effective inhibitors not only of
tumor growth but also angiogenesis in numerous in vivo models19. In order to take
additional advantage of a dual killing mechanism (tumor cells plus tumor endothelial cells)
and to further improve upon the efficacy of currently available oncolytic vectors, we
examined the strategy of using an “armed” oHSV expressing IL-12 combined with an MDA.
We have evaluated the preclinical therapeutic effects of NV1042 (expressing IL-12) in
combination with vinblastine and show that this combination enhances antitumor efficacy,
in part by, inhibiting angiogenesis.
Materials and methods
Cells and viruses
Vero (African green monkey kidney), MS1 (mouse pancreatic endothelial), C166 (mouse
yolk sac endothelial), CWR22 (human prostate cancer) and PC3 (human prostate cancer)
cells were obtained from American Type Culture Collection (Manassas, VA) and human
umbilical endothelial cells (HUVEC) from Lonza (Hopkinton, MA). HBME-1 (human bone
marrow endothelial) cells were a generous gift from Dr. K. Pienta (University of Michigan).
Vero cells were grown in DMEM supplemented with 10% calf serum and HUVEC in
EGM-2. PC3 cells were grown in FK-1 media containing 10% heat-inactivated fetal calf
serum (Hyclone, Logan, UT). Primary human prostate epithelial cells and its culture
medium PrEGM were maintained as described by the manufacturer (Lonza). Construction of
NV1023 and NV1042 has previously been described20. NV1023, derived from NV1020
(R7020), a HSV-1/HSV-2 intertypic recombinant developed as a vaccine strain21, contains
an insertion of LacZ into the ICP47 locus, deleting ICP47, US11, and US1020. NV1042 is
NV1023 with an insertion of murine IL-12 cDNA (p35 and p40 as a single polypeptide
separated by elastin motifs) expressed from a hybrid α4-TK promoter20.
Cell Viability assays
Viability assays were performed over a 3 day period using the MTS assay kit (Promega,
Madison, WI) in a 96-well format. The compounds used in this study included, Paclitaxel
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(Bristol-Myers Squibb, Princeton, NJ), docetaxel (Aventis Pharmaceuticals Inc.,
Bridgewater, NJ), vinblastine (APP Pharmaceuticals, Schaumburg, IL), epothilone-B
(EpoB) (Sigma-Aldrich), vincristine (Hospira Inc, Lake Forest, IL) and 2-methoxyestradiol
(2ME2) (Sigma-Aldrich).
Virus titration
Monolayer cultures of Vero cells grown in a six-well plate were infected with serial
dilutions of virus. After removal of virus inoculum, the cells were incubated in DMEM
supplemented with 1% inactivated FCS and 0.1%pooled human immunoglobulin at 37°C for
3-4 days until plaques were visible and counted.
Virus Replication assay
Cells were seeded in 12-well plate 1 day before infection and infected with NV1023 or
NV1042 at a multiplicity of infection (MOI) of 1. At the times indicated, cells were
harvested from the wells and viral titers were determined on Vero cells. Prostate cancer and
endothelial cell lines either remained untreated or were pretreated with vinblastine (0.1nM)
for 12h and thereafter, cells were infected with NV1023 or NV1042 at an MOI of 1.5. At 24
or 48h after infection, cells were scraped into the medium and subjected to three freeze-thaw
cycles. Virus titers were determined by plaque assays on Vero cells. Each concentration in
an experiment was plated in duplicate, and each experiment was performed three times.
Supernatants collected from single burst assays were assayed for IL-12 derived from
NV1042 at the indicated time points by ELISA(R&D Systems, Minneapolis, MN) and
normal goat IgG (2 μg/ml/well) (R&D Systems) was included as a species-specific control.
Cell susceptibility assays and Chou–Talalay analysis
Prostate cancer (PC3 and CWr22) and endothelial (HUVEC, HBM-1, C166 and MS1) cells
were seeded into 96-well plates at 1500-3000 cells per well. Viability assays will be
performed over a 3 day period using the MTS assay kit (Promega) with a concentration
range of MDA’s and varying MOI’s of oHSV. Dose-response curves were generated using
GraphPad v5.0 (San Diego, CA). For Chou–Talalay analysis, dose– response curves and
50% effective dose values (ED50) were obtained and compared at day 3. For ED50
determination, cells were incubated for 3 days with varying concentrations or MOIs of drug
and virus, respectively, and cell survival was then assessed using MTS assays. Dose–
response curves were fit to Chou–Talalay lines, which are derived from the law of mass
action and are described by the equation log(fa/fu)=m log D–m log Dm, in which fa is the
fraction affected (percent cell death), fu is the fraction unaffected (percent cell survival), D is
the dose, Dm is the median-effect dose (the dose causing 50% of cells to be affected, that is,
50% survival), and m is the coefficient signifying the shape of the dose–response curve. The
combination index (CI)-isobologram by Chou and Talalay22 was used to analyze virus and
drug combinations. Fixed ratios of virus and drug concentrations and mutually exclusive
equations were used to determine CIs. All experiments were repeated at least three times.
Tube formation assay
HUVEC cells (~90,000 cells/well) were added to Matrigel™ (BD Biosciences) -coated 24-
well plates. Four hours later, docetaxel (10nM), vinblastine (10 nM), vincristine (10nM),
EpoB (10 μM) or 2ME2 (10 μM) were added in triplicate. For combination studies, NV1023
or NV1042 (MOI 1) with or without vinblastine (1 nM) were added. Twenty hours later tube
formation was quantified by counting the branching points for each wellby light microscopy.
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In vivo studies
CWr22 cells (5 × 106 cells) were implanted subcutaneously into the flanks of 6-to 8-week-
old balb/c nu/nu mice (n=8 mice per group).When the tumor volume reached 75-150
mm3(~14 days after implantation) mice were stratified by tumor volume and then randomly
assigned to treatment groups (n=8 per group).Virus [NV1023 or NV1042; 5×105 plaque-
forming units (pfu)] or virus suspension buffer (PBS with 10% glycerol) was injected
intratumorally on days 13 and 15 after tumor implantation. Vinblastine monotherapy or its
combination with virus was administered intraperitoneally on day 15 at 0.35 mg/kg for nine
consecutive days. All procedures were approved by the MGH Subcommittee on Research
Animal Care. Tumor volume was calculated using the formula width (mm)2 × length (mm)
× 0.52.
CD31 immunohistochemistry and quantification
Mice (n=3/group) were treated as described above and at day 30 post-implantation tumors
were harvested, frozen and cut into tissues sections. Tissue sections were stained with a rat
anti-mouse CD31 antibody (BD Biosciences, San Jose, CA) followed by secondary anti-rat
IgG conjugated to HRP (GE Healthcare, Piscataway, NJ). CD31+ staining was revealed with
3,3′-diaminobenzidine (DAB) histochemistry (Vector Laboratories, Burlingame, CA).
Sections were counterstained with hematoxylin (Sigma, St. Louis, MO). Tumor microvessel
density was quantified for all treatment groups. At least 6-10 representative 40X fields per
view were captured as epifluorescent digital images using a Spot digital camera (Spot
Diagnostic instruments, Sterling, MI). To calculate microvessel density, area occupied by
CD31-positive microvessels and total tissue area, per section were quantified using Image J
software (NIH, Bethesda, MD). Microvessel density was then calculated as a percentage of
CD31 stained per tumor section.
Prostate organ cultures
Prostate organ cultures were performed as previously described23. Briefly, tissue fragments
were incubated with NV1023 (1 × 106pfu) or NV1042 (1 × 106pfu) for 1 h in direct contact
and thereafter, placed on a semi-submersed collagen sponge (Ultrafoam™, Davol Inc.,
Warwick, RI) for 3 days. Tissue specimens (8 μm) were stained with anti-HSV-1 gC
(Virusys Corp., Sykesville, MD, USA) or anti-cytokeratin-8/18 (UCD/PR-10.11,
Dakocytomation, Carpinteria, CA, USA) antibodies as previously described. Virus titers
were determined by titration of tissue homogenates on Vero cells using plaque assays.
Tissues weights were determined to correct for viral titer concentrations. (Average±S.E.M).
Each color dot indicates a different prostate surgical specimen that was separately infected
with either NV1023 or NV1042 (n=5).
Statistical analysis
All statistical analyses were done using GraphPad prism v5. For comparison of efficacy and
mechanism of efficacy, unpaired Student’s t test (two tailed) was used to analyze
significance between two treatment groups.
Results
Evaluation of a panel of MDA’s on endothelial and prostate cancer cell lines
MDA’s have been shown to have broad-based antitumor and antiangiogenic properties19,24.
We initially screened a series of MDA’s (docetaxel, paclitaxel, vinblastine, vincristine,
epothilone-B and methoxyestradiol) on a panel of human (HUVEC, HBME1) and mouse-
(MS1 and C166) derived endothelial and human prostate cancer cell lines. While the
majority of MDA’s tested yielded potent cytotoxic effects on all four endothelial cell lines,
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vinblastine (VB), was consistently superior (EC50= 0.18-1.7 nM), demonstrating potent
dose-dependent endothelial cell killing (Figure 1A; Table 1). In vitro matrigel assays, which
partially recapitulate the mechanisms of neovascularizaion observed in vivo, confirmed that
VB was highly effective at inhibiting tube formation of HUVEC cells (Supplementary
Figure 1). Furthermore, in prostate cancer cell lines, VB was more or equally potent as the
other MDA’s tested. For example, in the androgen-dependent CWR22 cell line, the
cytotoxic effects of VB paralleled vincristine, while VB’s cytotoxic effects on the androgen-
independent PC3 cell line was similar to vincristine, docetaxel and paclitaxel (Figure 1B;
Table 1). In contrast, EpoB and 2-ME2 had negligible effects on both endothelial and tumor
cell lines. Lastly, when endothelial (HUVEC and HBME) or prostate cancer cells (CWR22
and PC3) were treated with MDA’s for only 3 hrs and then washed away, VB was still
cytotoxic, suggesting that even transient exposure of VB is effective (Supplemental Figure
2).
In vitro assessment of oHSV and MDA combination
Previously, we reported that NV1023 and IL-12 secreting NV1042 were effective in vitro
and in vivo at killing mouse prostate cancer cells8-10. To evaluate the cellular
permissiveness of the human CWR22 and PC3 cancer cell lines toward NV1023 and
NV1042, we performed viral burst assays. Figure 2A shows that by 48 hrs, virus production
in CWR22 cells peaked, resulting in a ~32-fold increase in viral titers over input virus. By
72 hrs, the generation of virus progeny had plateaued. In PC3 cells, NV1023 and NV1042
virus production steadily increased over a 72 hr time period, resulting in a ~22-fold
enhancement over input virus. Dose-response curves reflected the above findings, with both
NV1023 and NV1042 more cytopathic toward CWR22 [EC50= 0.24; Multiplicity of
infection (MOI)] than PC3 (EC50= 0.85 MOI) cells (Figure 2B). In addition, VB treatment
of PC3 (EC50 = 7.8 nM) and CWR22 (EC50= 4.2 nM) resulted in a dose dependent response
over a 3d period (Figure 2C). IL-12 secretion after NV1042 infection showed relatively high
levels in both prostate cancer cell lines over a 72 period, even though differences in viral
titers were observed between cell lines (Figure 2D).Lastly, both NV1023 and NV1042 (data
notshown) can replicate to various degrees in the four aforementioned endothelial cell lines
(Supplemental Figure 3).
We used the combination index (CI) method of Chou-Talalay22 to assess whether the
parental virus NV1023 in conjunction with VB could promote CWR22 or PC3 cell killing in
a synergistic manner. A CI value of less than1 indicates synergism and CI>1 indicates
antagonism. Mild synergism (CI~0.8) was observed when NV1023 or NV1042 (EC50= 0.24
MOI) and VB (EC50 = 4.2 nM) were added together in CWR22 cells (Figure 3). We further
explored whether the observed synergistic effect was dependent on the timing of drug
administration. A similar synergistic effect (CI~0.8) was observed regardless of whether VB
was added 12hr before or after treatment of NV1023 or NV1042 (Figure 3C). Lastly,
docetaxel but not EpoB could be substituted for VB in combination with NV1023 or
NV1042 resulting in mild synergy (Figure 3C). In PC3 cells, the combination of NV1023 or
NV1042 (EC50 = 0.85 MOI) with VB (EC50 =7.8 nM) resulted in an additive effect
regardless of the order of administration. We also addressed whether the observed
synergistic effects were due to increased oHSV replication by VB. The addition of a
nontoxic concentration of VB (0.1 nM) to NV1023 neither increased nor decreased viral
titers as compared to NV1023 alone at 48 hr after infection in single-step growth curve
assays (Figure 2E). Lastly, in matrigel tube formation assays, we observed that the
combination of either NV1023 or NV1042 (MOI 0.2) with VB (1 nM) was significantly
more effective at disrupting tube formation than any single agent alone (Figure 4).
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Preclinical evaluation NV1023 or NV1042 with vinblastine in CWR22 xenografts
Next, we evaluated the in vivo antitumor efficacy of NV1023 or NV1042 in combination
with VB in subcutaneous CWR22 tumors in athymic mice. Initially, doses of individual
therapies were established to determine conditions resulting in tumor size reductions of
20-50% (data not shown). Mice were treated with either mock control, NV1023 or NV1042
(5×105pfu) on days 13 and 15, and/or VB (0.35 mg/kg; for 9 consecutive days) starting on
day 15 (Figure 5A). By 32 days after tumor implantation, a statistically significant decrease
in tumor volume was observed between control (2356±746) and all of the treatment groups
(P < 0.05, *; P < 0.01, **) (Figure 5B). As compared with mock, treatment with NV1023
(1575±552), NV1042 (1087±254) and VB (1623±611) resulted in a notable reduction in
tumor size; whereas the combination of NV1023/VB (1143±321) was superior to either
therapy alone. Importantly, NV1042 plus VB (487+175, P < 0.01, ***), was significantly
more effective than NV1023 plus VB or NV1042 alone. These combination therapies
appeared to be nontoxic to mice as their body weight were not statistically different
(Supplemenary figure 4). As the combination of NV1042/VB appeared to be more
efficacious than any of the other treatment groups in reducing tumor volume, we
hypothesized that this might be due, in part, to the combined antiangiogenic contributions of
IL-12 and VB. This was tested using anti-CD31 antibody staining, which marks endothelial
cells, on CWR22 tumor tissue sections. This revealed a reduction in CD31+ cells in the
NV1042 plus VB treatment group as compared to the other treatment groups (Figure 5C). A
statistically significant reduction in the number of CD31+ cells was observed in tumors
treated with NV1042 plus VB as compared to all of the other treatment groups(P<0.05, **)
(Figure 5D). In addition, statistically significant differences were also observed between
NV1023and NV1042 treatment groups (P< 0.05, *), which is consistent with a previous
report demonstrating a reduction of CD31-positive cells in murine prostate tumors treated
with NV10428.
Lastly, we wished to confirm specificity in an additional model system representative of
human prostate cancer. Recently, we reported the use of human prostate organ cultures using
surgical specimens derived from radical prostatectomies to assess oHSV target specificity
and replication competence23. We exploited this system to address the target specificity and
replication competence of NV1023 and NV1042. At 3 days after infection, anti-HSV gC
staining revealed that both NV1023 and NV1042 appeared to preferentially localize to the
prostatic glandular regions in primary human prostate cancer tissues (Figure 6A). The
staining of serial sections with anti-cytokeratin 8/18 antibody, which specifically stains
luminal epithelial cells, confirmed that both vectors were restricted to epithelial cells and is
in agreement with the restricted specificity of oHSV’s previously seen in prostate cancer
tissues23. NV1023 and NV1042 replicated to similar degrees in five different prostate cancer
tissue specimens examined (Figure 6B). Interestingly, the amount of replication for both
viruses was similar in cultures from the same patient (same color dots, Fig 6B), as opposed
to different patients.
Discussion
The discovery that tumors induce angiogenesis to generate new blood vessels for their
growth and progression25,26 has recently led to numerous anti-angiogenic therapeutic
strategies as well as demonstrated promise in improving the outcomes in cancer patients27.
Our study focused on implementing a treatment regimen for prostate cancer by combining
the antitumor and antiangiogenic activities of an “armed” oncolytic oHSV (NV1042) with a
cytotoxic microtubule disrupting agent, vinblastine, in order to improve antitumor efficacy.
Of the six microtubule disrupting agents (MDA) tested, we found vinblastine to be the most
potent at killing not only prostate cancer cells but also all endothelial cells. This is in
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agreement with published observations that show that continuous treatment of VB at a low
dose, can result in antiangiogenesis and sustained tumor regression28.
Strategies of “arming” oHSV’s with anti-angiogenic transgenes have also shown promise in
various preclinical models. For instance, IL-12 expressing NV1042 has shown enhanced
therapeutic efficacy over NV1023 in subcutaneous or metastatic lung murine prostate cancer
TRAMP-C2 tumors9,10 and C3(1)/T-Ag breast cancers29. In addition, “armed” oHSV’s
expressing other antiangiogenic agents such as dominant-negative fibroblast growth factor
receptor, platelet factor-4 or angiostatin have been shown to substantially decrease blood
vessel formation and increase survival30-32.
In vivo, we demonstrate that the combination of IL-12 expressing NV1042 with low dose
VB can enhance CWR22 tumor killing by partially impairing endothelial cell growth and/or
neovascularization. VB alone administered at a low dose (0.35mg/kg) over a 9-day period,
or NV1042 monotherapies were effective at promoting tumor regression. However, in
combination a superior antitumor effect was observed, accompanied by minimal adverse
side effects, such as stable body weight. The decreased tumor growth elicited by combining
NV1042 with VB was most likely due to the cooperative effect on blood vessels as shown
by the significant decrease in CD31+ blood vessels as well as the cytotoxic effects on tumor
cells by either agent. Angiogenesis is a complex process that involves multiple regulatory
proteins and endothelial cell activation. Endothelial cells that make up existing blood vessels
are activated to multiply and migrate as surrounding basement membrane and extracellular
matrix is degraded to make way for new capillaries. IL-12 primarily modulates tumor
growth by the recruitment of immune cells such as natural killer cells and T cells33. Our
previous work addressed the antitumor and anti-angiogenic properties of the NV1042
expressing IL-12 virus in both syngeneic and transgenic mouse models of prostate
cancer8-10. In this paper, our study focused on the anti-angiogenic effects of NV1042 in
combination with vinblastine in human prostate cancers. Therefore, we utilized athymic
xenograft models of prostate cancer, which lack T-cells and therefore, eliminates the tumor
regression effects contributed by T-cells34. However, nude and SCID mice have relatively
normal levels of NK-cells, which have been shown to contribute, in part, to the inhibition of
angiogenesis by IL-1211,35. Our data show that NV1042 was superior to NV1023 either
alone or in combination with vinblastine in slowing tumor growth in nude mice and that
these results correlated with the percentage CD31+ blood vessels in tumor xenografts as a
function of treatment condition.
Previous studies have shown that chemotherapy can enhance oncolytic viral replication36. In
vitro, we did not observe any significant change in NV1042/NV1023 viral yield in the
presence of vinblastine. This is in accordance with our previous findings, where
pretreatment with nontoxic concentrations of taxanes had negligible effects on G47Δ
replication13. A similar dose-range of either docetaxel or paclitaxel in combination with
G47Δ significantly increased prostate cancer cell killing13. In the present study, irrespective
of treatment sequence with the combination of NV1023/NV1042 and VB, a weak synergy-
to-additive effect was observed. Because α-herpesviruses are dependent on intact
microtubules for efficient transport and egress37, MDA treatment would be expected to
compromise NV1023/N1042 replication, particularly under conditions where vinblastine
was added prior to virus infection. Disruption of microtubules by MDA’s such as
nocodazole or taxol (ie., paclitaxel), have shown varying effects on HSV-1 transport and
replication. Avitabile and colleagues reported that neither MDA significantly affected the
release of free virus into the media at micromolar concentrations38. In contrast, Kotaskis
etal, reported that treatment of synchronized cells with nocadozale or taxol at similar
concentrations prevented optimal HSV-1 replication39. These discrepancies may be
attributed to whether cells were synchronized or alternatively, due to differences in the
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sensitivities of cells to nocodazole or taxol. A likely explanation for the observed weak
synergy-to-additive effects is that at low VB concentrations, microtubules are minimally
disrupted, which would allow for sufficient NV1023/NV1042 replication. In agreement
these observations, the addition of G207 to nanomolar concentrations of paclitaxel resulted
in weak synergy in promoting thyroid cancer cell killing with minimal effects G207
replication40.
Combination therapy regimens with anti-angiogenic agents will be critical to treat prostate
cancer, as microvessel density has been shown to correlate strongly with Gleason grade and
predict disease progression41,42. Although a recently concluded phase III trial of prostate
cancer using bevacizumab (anti-VEGF antibody) in addition to the current standard of
docetaxel and prednisone was negative43 other antiangiogenic strategies are worth exploring
and the use of dual angiogenesis inhibition with direct oncolytic oHSV therapy is an
attractive strategy for prostate cancer, and can hopefully be used to overcome resistance that
is observed with anti-angiogenic monotherapies44.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Cytotoxic effects of MDA’s. (A) HUVEC (human umbilical vein endothelial cells) primary
cultures and endothelial cell lines MS1 (mouse pancreatic), C166 (mouse yolk sac),
HBME-1 (human bone marrow) and (B) Human CWR22 and PC3 prostate cancer cell lines
were treated with increasing concentrations of the indicated MDA’s. MTS assays were
performed on day 3 to determine the extent of cell killing.
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Figure 2.
Analysis of NV1023 and NV1042 replication and effects on prostate cancer cell killing (A)
Single burst assays were performed using either NV1023 or NV1042 (MOI =1.5) on
CWR22 or PC3 cells over a 72 hr period. Virus (cell pellet plus supernatants) on days 1, 2
and 3 post-infection and viral titers (pfu/ml) determined by plaque assay on Vero cells as
described previously13. Input virus: ~4×105 plaque forming units (pfu; indicated by arrow).
(B) Cell susceptibility assays were performed using NV1023 or NV1042 on either CWR22
(left) or PC3 (right) prostate cancer cells. Cell lines were inoculated with the indicated
MOI’s of virus and cell killing was evaluated by MTS assay on day 3 (error bars represent
S.E.M.). (C) PC3 (open bar) or CWR22 (solid bar) prostate cancer cells were treated with
increasing concentration of VB (0.01-100 nM) and MTS assays were performed to generate
dose-response curves. (D) Supernatants collected from single burst assays were assayed for
IL-12 derived from NV1042 by ELISA at the indicated time points. NV1023 was used as a
control vector to normalize for background andnormal goat IgG control was also included to
demonstrate specificity for murine IL-12. (E) Prostate cancer (PC3 and CWR22) and normal
prostate epithelial (PrEC) cells were incubated in the presence or absence of non-toxic
concentrations of VB (0.1 nM) for 12h and thereafter, cells were infected with NV1023
(MOI of 1.5) for 72 hrs. Virus titers were determined by plaque assay on Vero cells. Note
that virus replication is not altered in the presence of VB and is negligible in PrEC.
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Figure 3.
Combination-Index analysis. Fraction affected (Fa) versus combination index plots were
generated using the method of Chou and Talalay22 to determine the extent of synergy if any
for either vinblastine (VB), docetaxel (Doc) or epothilone-B (EpoB) in combination with
NV1023 or NV1042 in CWR22 (upper panels) and PC3 (lower panels) cell lines. (+)
indicates simultaneous oHSV and drug addition; (→) indicates oHSV inoculation 24 hrs
before drug treatment; (←) indicates drug treatment 24 hrs prior to oHSV infection.
Synergistic effects are defined as combination index (CI) < 1 additive effects are CI=1, and
antagonistic effects are CI>1. Note that the dotted line in each plot indicates a reference
point of a CI value of 1.
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Figure 4.
Increased antiangiogenic effects ofNV1042/vinblastine combination in an in vitro tube
formation assay. HUVEC cells were plated on matrigel-coated plates and either remained
untreated (Neg.) or treated with NV1023 or NV1042 (MOI 1), vinblastine (1nM) or their
combination. Twentyhrs later, tube formation was scored. Representative fields are shown
for each condition (A) and the number of tubes/field was quantified (B). Each treatment was
performed in triplicate. Student’s t test was used to determine statistical significance
between the indicated control and treatment groups. Bars represent average ± S.E.M..*, P<
0.01 for NV1023+VB and NV1042+VB verses NV1023 alone, NV1042 alone, VB alone or
untreated.
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Figure 5.
In vivo efficacy studies. (A) Schematic illustrating the dosing and scheduling of single and
combination treatment regimes in mice bearing s.c. CWR22 tumors. (B) Assessment of
CWR22 tumor growth. Virus [NV1023 or NV1042; 5×105 plaque-forming units (pfu)] or
virus suspension buffer (PBS with 10% glycerol) was injected intratumorally on days 13 and
15 after tumor implantation. Vinblastine was administered intraperitoneally at 0.35 mg/kg
on day 15 for nine consecutive days. *, P< 0.05 for mock (n = 8) versus NV1023 only (n =
8) and VB only (n = 7); **, P< 0.01 for mock verses NV1042 only (n = 6) and NV1023 +
VB (n = 6); ***, P< 0.01 for NV1042+VB (n = 7) verses NV1042 only and NV1023 + VB
at day 32. (C) Evaluation of CD31+ staining (brown) as a function of treatment condition.
Mice (n=3/group) were treated as described above and at day 30 post-implantation tumors
were harvested, frozen and cut into tissues sections. Tissue sections were stained with a rat
anti-mouse CD31 antibody and were counterstained with hematoxylin. (D) Quantification of
CD31-positive staining. Tumor microvessel density was quantified for all treatment groups.
Tumor microvessel density was compared between all treatment groups and untreated
control group. (Mean ± S.E.M); * P< 0.04 for NV1023 verses NV1042; **, P<0.03 for
NV1042 verses NV1042/VB.
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Figure 6.
Analysis of NV1023 and NV1042 infection of prostate cancer surgical samples. Tissues
were incubated with NV1023 (1 × 106pfu) or NV1042 (1 × 106pfu) for 1 h in direct contact
and thereafter, placed on a semi-submersed collagen sponge for 3 days. (A) Tissue
specimens were stained with anti-HSV-1 gC (upper panels) or anti-cytokeratin-8/18 (lower
panels) antibodies. Sections were counterstained with hematoxylin. Note the partial overlap
between anti-HSV gC and cytokeratin-8/18+ staining. (B) Evaluation of NV1023 or
NV1042 replication in prostate organ cultures. Each color dot indicates a different prostate
surgical specimen. Horizonal line denotes the average viral titer for the two groups, which
are statistically not significant. Note that infection with NV1023 or NV1042 resulted in
similar viral titers. The five specimens examined represent Gleason Scores of either 3+3=6
or 3+4=7.
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